Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | +3.40% | -3.18% | +9.60% |
May. 30 | Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results | CI |
May. 15 | Transcript : OncoCyte Corporation, Q1 2024 Earnings Call, May 15, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.60% | 36.62M | |
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.48B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-29.59% | 508M |
- Stock Market
- Equities
- OCX Stock
- News OncoCyte Corporation
- Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating